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Kir2.1 InteractomeMapping Uncovers PKP4 as
aModulator of the Kir2.1-Regulated Inward
Rectifier Potassium Currents
Sung-Soo Park1,‡,Daniela Ponce-Balbuena2,‡, Rork Kuick3,†,Guadalupe Guerrero-Serna2,
Justin Yoon1 , Dattatreya Mellacheruvu1, Kevin P. Conlon1, Venkatesha Basrur1 ,
Alexey I. Nesvizhskii1,4 , José Jalife2,5,6,*, and Jean-François Rual1,*
Kir2.1, a strong inward rectifier potassium channel en-
coded by the KCNJ2 gene, is a key regulator of the resting
membrane potential of the cardiomyocyte and plays an im-
portant role in controlling ventricular excitation and action
potential duration in the human heart. Mutations in KCNJ2
result in inheritable cardiac diseases in humans, e.g. the
type-1 Andersen-Tawil syndrome (ATS1). Understanding
the molecular mechanisms that govern the regulation of
inward rectifier potassiumcurrents byKir2.1 in both normal
and disease contexts should help uncover novel targets for
therapeutic intervention in ATS1 and other Kir2.1-associ-
ated channelopathies. The information available to date
on protein-protein interactions involving Kir2.1 channels
remains limited. Additional efforts are necessary to provide
a comprehensive map of the Kir2.1 interactome. Here we
describe the generation of a comprehensive map of the
Kir2.1 interactome using the proximity-labeling approach
BioID.Most of the 218 high-confidenceKir2.1 channel inter-
actions we identified are novel and encompass various
molecular mechanisms of Kir2.1 function, ranging from in-
tracellular trafficking to cross-talk with the insulin-like
growth factor receptor signaling pathway, as well as lyso-
somal degradation. Our map also explores the variations in
the interactome profiles of Kir2.1WT versus Kir2.1D314-315, a
trafficking deficient ATS1mutant, thus uncoveringmolecu-
lar mechanisms whose malfunctions may underlie ATS1
disease. Finally, using patch-clamp analysis, we validate
the functional relevance of PKP4, one of our top BioID inter-
actors, to the modulation of Kir2.1-controlled inward recti-
fier potassium currents. Our results validate the power of
our BioID approach in identifying functionally relevant
Kir2.1 interactors and underline the value of our Kir2.1 inter-
actome as a repository for numerous novel biological
hypotheses onKir2.1 andKir2.1-associated diseases.
The strong inward rectifier potassium channel Kir2.1 is a
key regulator of the resting membrane potential of the car-
diomyocyte and plays an important role in controlling ven-
tricular excitation and action potential duration in the
human heart (1–3). Both loss and gain of function muta-
tions in KCNJ2, the gene encoding Kir2.1, result in inherit-
able cardiac ion channel diseases. For example, several
KCNJ2 loss of function mutations are associated with the
inheritable type-1 Andersen-Tawil syndrome (ATS1), also
known as long QT syndrome type 7, which predisposes
patients to cardiac arrhythmias and sudden death (4, 5).
On the other hand, KCNJ2 gain-of function mutations give
rise to the type-3 variant of the short QT syndrome, which
also results in increased risk of sudden cardiac death (6).
Understanding the molecular mechanisms that govern the
regulation of inward rectifier potassium currents by Kir2.1
in both normal and disease contexts should help uncover
novel targets for therapeutic intervention in ATS1 and
other Kir2.1-associated channelopathies.
Over the last 20 years, analyses of the Kir2.1 channelosome
using genetic, pharmacological, and molecular approaches
have greatly contributed to our understanding of its function
and its role in cardiac diseases (3, 7, 8). Expression, trafficking,
localization, and function of Kir2.1 are regulated by its interac-
tions with multiple proteins. To date, 24 putative Kir2.1 interac-
tors have been identified, out of which 16 are high-confidence
Kir2.1 interactors (supplemental Table S1). For example, Leo-
noudakis et al. showed that the PDZ-binding motif of Kir2.1
interacts with the SAP97, CASK and LIN7C proteins, members
of the membrane-associated guanylate kinase (MAGUK) family,
which work both as scaffolding proteins for large
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macromolecular structure and as trafficking regulators (9–11).
Recently, we and others demonstrated that the Kir2.1 channel
and the voltage-gate sodium channel, Nav1.5, belong to com-
mon multiprotein channelosomes, enabling one to regulate the
other’s expression (12–15). It has become apparent that ion
channel proteins do not function in isolation but are part of
large, multi-protein complexes, comprising not only the ion
channels and their auxiliary subunits, but also components of
the cytoskeleton, regulatory post-translation modification
enzymes, trafficking proteins, extracellular matrix proteins, and
even other ion channels (3, 7, 8). Notwithstanding the signifi-
cance of the aforementioned biochemical studies, the informa-
tion available on protein-protein interactions involving Kir2.1
channels, with only 16 high-confidence Kir2.1 interactors,
remains limited. Additional efforts are necessary to provide a
comprehensive map of the Kir2.1 interactome.
The relatively low number of known Kir2.1 interactors
described to date in the literature can be attributed to its
hydrophobic nature and the technical challenges associated
with its biochemical manipulation. Similarly, some members
of the protein complexes associated with Kir2.1 may mediate
weak, transient interactions that are lost during “standard”
biochemical affinity purification in the various lysis, wash,
and elution steps. BioID, a cutting-edge proximity-labeling
technology that is particularly well-suited to mapping protein
interactions for low-solubility proteins, overcomes many of
the above barriers imposed by conventional screening meth-
ods (16–18). BioID is based on the fusion of a promiscuous
E. coli biotin protein ligase (BirA*) to a bait protein (17). On
expression of the BirA*-bait fusion protein in cell and subse-
quent addition of biotin, proteins that are near-neighbors of
the fusion protein are biotinylated in a proximity-dependent
manner. Biotinylated proteins are then isolated by affinity
capture and identified by MS (MS), thus uncovering the BioID
interactome of the bait protein under investigation (17). A key
advantage of this proteomic approach resides in the fact that
the bait, e.g. the low-solubility channelosome protein Kir2.1,
does not need to be biochemically purified in native complex
and that transient interactions can be captured (16–18).
Here, we present the generation of a comprehensive map
of the Kir2.1 interactome using BioID. Bait proteins used in
our BioID proteomic screens include not only Kir2.1WT but
also Kir2.1D314-315, an ATS1-associated mutation, which
blocks Kir2.1 Golgi export (4, 19, 20). Thus, beyond interac-
tome mapping, our BioID experiments also aim to capture
the differences between the protein interaction profiles of
Kir2.1WT versus Kir2.1D314-315 proteins, and to uncover the
molecular mechanisms whose malfunctions underlie ATS1
disease. A total of 218 high-confidence Kir2.1 BioID interac-
tors were identified, including 75 Kir2.1WT-preferred interac-
tors, 66 Kir2.1D314-315 mutant-preferred interactors and 77
proteins that interact with both WT and mutant Kir2.1 pro-
teins. Finally, we present patch-clamp analyses of one of our
top BioID interactors, PKP4, which validate its functional rele-
vance to modulation of Kir2.1-regulated inward rectifier po-
tassium currents.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies—For the transmembrane protein con-
trol (TM-CTRL), the amino acid sequence IIFRTLFGSLVFAIFLILMIN
of the Saccharomyces cerevisiae P25353 protein transmembrane do-
main, which has no homology to any human proteins, was selected
and a humanized codon sequence was synthesized (supplemental
Table S2). The protein-encoding Open Reading Frames (ORFs) of
Kir2.1WT (NM_000891.2), Kir2.1D314-315, and TM-CTRL were first
cloned by Gateway recombination cloning from the cDNA plasmids
into the Gateway Donor vector pDONR223 to generate Entry clones,
as previously described (21) (primer sequences are shown in
supplemental Table S2). The Gateway clone of PKP4 (EL733946)
was obtained from the Center for Cancer Systems Biology (CCSB,
Harvard Medical School, Boston) human ORFeome collection (21).
Protein-encoding ORF/s were then subcloned from the Entry clones
into the Gateway Destination vectors pDEST-pcDNA5-FRT-BirA*-
FLAG-N-term and pDEST-pcDNA3-HA (18, 22). A target sequence of
PKP4 for CRISPR/Cas9 (supplemental Table S2) was selected using
CHOPCHOP web tool (23) and cloned into pX459 (Addgene, Water-
town, MA, 62988), as previously described (24). The following pri-
mary and secondary antibodies were used in the Western blot analy-
ses: FLAG (Sigma, Kawasaki, Kanagawa, Japan, A8592) and goat
a-rabbit IgG (Cell Signaling, Danvers, MA, 7074).
Cell Culture—Flp-In T-REx 293 cells (ThermoFisher Scientific,
Waltham, MA, R78007) were maintained following the manufacturer’s
guideline and were transfected with the Gateway expression vectors
(pcDNA5-FRT-BirA*-FLAG-N-term) of Kir2.1WT, Kir2.1D314-315, and
TM-CTRL using polyethylenimine (Polysciences, Warrington, PA,
23966-2) (co-transfection with pOG44) as previously described (25).
Stable cells were selected using 200 mg/ml hygromycin B (Invitrogen,
Carlsbad, CA, 10687010). HEK293T cells were cultivated in DMEM
(Invitrogen, 11995) medium supplemented with 10% FBS (Sigma,
F0926) and penicillin/streptomycin (Invitrogen, 15140) and were
transfected with protein expression vectors using PEI.
Affinity Purification of Biotinylated Proteins—BioID experiments
were performed as previously described (18) with some minor modifi-
cations. Triplicate BioID experiments were performed for each of the
bait proteins: BirA*-Kir2.1WT, BirA*-Kir2.1D314-315 and BirA*-TM-
CTRL. Cells were incubated for 24 h with 10 mg/ml tetracycline and
50 mM biotin. After washing with cold PBS, cells (n = 3 3 107) were
lysed for 30 min at 4°C with lysis buffer [50 mM Tris pH 7.2, 150 mM
NaCl, 10% glycerol, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.2% SDS, protease inhibitor (Roche, Basel, Switzerland, 05 056 489
001), phosphatase inhibitor (Sigma, P0044), and Benzonase (Sigma,
E1014)]. The cleared cell lysates were incubated with 30 mL of strepta-
vidin bead slurry (ThermoFisher Scientific, 20361) for 3 h at 4°C. The
beads were washed with washing buffer (50 mM Tris pH 7.2, 150 mM
NaCl, 10% glycerol, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.2% SDS) four times and then with rinse buffer (50 mM Tris pH 7.2,
150 mM NaCl, 0.5% Nonidet P-40) three times. The beads were
washed with fresh 50 mM NH4HCO3 three times and stored at 280°C.
Protein Identification by Mass Spectrometry and BioID Hit
Selection—The samples were analyzed in the Proteomics Resource
Facility of the Department of Pathology at the University of Michigan
for protein identification. Briefly, upon reduction (10 mM DTT) and al-
kylation (65 mM 2-chloroacetamide) of the cysteines, proteins were
digested overnight with 500 ng of sequencing grade, modified trypsin
(Promega, Madison, WI, V5111). Resulting peptides were resolved
on a nano-capillary reverse phase column (Acclaim PepMap C18,
2 mM, 50 cm, ThermoFisher Scientific, ES803) using 0.1% formic
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acid/acetonitrile (ACN) gradient at 300 nL/minute (2–25% ACN in 108
min, 25–40% in 20 min, followed by a 90% ACN wash for 10 min
and a further 30 min’ re-equilibration with 2% ACN) and directly
introduced into Orbitrap Fusion Tribrid Mass Spectrometer (Thermo-
Fisher Scientific). MS1 scans were acquired at 120k resolution. Data-
dependent high-energy C-trap dissociation MS/MS spectra were
acquired with top speed option (3 s) following each MS1 scan (rela-
tive CE ;32%). Proteins were identified by searching the data
against Homosapiens database containing both canonical and iso-
form protein entries (SwissProt v2016-11-30; total number of entries:
42054) using Proteome Discoverer (v2.1, ThermoFisher Scientific,
June 2016) with enzyme specificity for trypsin. Search parameters
included MS1 mass tolerance of 10 ppm and fragment tolerance of
0.1 Da; two missed cleavages were allowed; carbamidomethylation
of cysteine was considered fixed modification and oxidation of me-
thionine, deamidation of asparagine and glutamine were considered
as variable modifications. False discovery rate (FDR) was determined
using target-decoy strategy and proteins/peptides with a FDR of
1% were retained. A stringent set of criteria were used for the
selection of the high-confidence Kir2.1 BioID hits: (1) average SpC
(spectral counts) in either the Kir2.1WT or the Kir2.1D314-315 BioID ex-
periment . 10; (2) SAINT probability (27, 28) . 0.9; and (3) primary
fold change FC-A score (28) . 7. The data obtained with the TM-
CTRL bait were used as negative controls for the calculations. One
of the high-confidence Kir2.1 BioID interactors has been identified
with a single peptide, i.e. NACA2. The spectra annotation for NACA2
is provided in the supplemental Fig. S1.
Kir2.1WT versus Kir2.1D314-315 Interactome Profiling—We classi-
fied the BioID hits as Kir2.1WT-preferred or Kir2.1D314-315 -preferred
interactors based on the normalized Kir2.1WT/D314-315 SpC ratio “R “.
For a given protein, “R “ represents the ratio of the SpC observed for
this protein in the Kir2.1WT and Kir2.1D314-315 BioID experiments.
Specifically, R was calculated as follows. First, the number of SpC
observed for a given protein in a given triplicate Kir2.1WT or
Kir2.1D314-315 BioID experiment was normalized to the Kir2.1WT BioID
experiment #1 by dividing SpC by the ratio of the Kir2.1 SpC
observed in this given experiment to the Kir2.1 SpC observed in the
Kir2.1WT BioID experiment #1 (supplemental Table S3, columns X-
AE). Second, after adding one to each SpC and Log2-transformation
(columns AF-AK), we calculated the average Log2-transformed,
normalized SpC for both the Kir2.1WT and Kir2.1D314-315 BioID
experiments (columns AL and AM). The ratio R was then calculated
by performing a power of 2 transformation (column AN). The statis-
tical significances of the difference between the Kir2.1WT and
Kir2.1D314-315 BioID experiments were computed using a two-sam-
ple t test on the Log2-transformed data (column AO). Kir2.1 BioID
hits with both R . 2 and p , 0.05 were classified as Kir2.1WT-pre-
ferred interactors whereas proteins with both R , 0.5 and p ,
0.05, i.e. a 2-fold decrease, were classified as Kir2.1D314-315-mu-
tant preferred interactors (column AP). A permutation analysis was
performed to estimate the false discovery rate (FDR , 0.007).
Immunofluorescence (IF) Staining Experiments—IF staining ex-
periments were performed utilizing either HEK293 cells or freshly iso-
lated rat ventricular myocytes, as previously described (15) using the
following primary and secondary antibodies: PKP4 (ThermoFisher
Scientific, PA5-66855, dilution 1/500), Kir2.1 (Alomone Labs, Jerusa-
lem, Israel, AGP-044, dilution 1/20), Actinin (Sigma, SAB4503474, 1/
300), GM130 (Novus Biologicals, NBP2-53420; dilution 1/200), FLAG
(Sigma-Aldrich; F3165, dilution: 1/50), Alexa Fluor 488 donkey anti-
mouse, Alexa Fluor 594 donkey anti-guinea pig and Alexa Fluor 647
donkey anti-rabbit (Jackson ImmunoResearch, West Grove, PA,
dilution 1/400).
Patch-Clamping Experiments—HEK293 cells were grown in 60-
mm dishes and, upon reaching ;60–70% confluence, were transi-
ently transfected using X-tremeGENE HP DNA transfection reagent
(Sigma, 6366244001) following the supplier’s directions. The DNA
plasmids used in the patch-clamp experiments were: CRISPR/Cas9
construct pX459-gPKP4 and negative control pX459 and protein
expression vectors pcDNA3-HA-PKP4 and “empty vector” nega-
tive control pcDNA3-HA. A GFP-expression vector was also co-
transfected to visualize the transfected cells during the patch-
clamp experiments. Patch-clamp experiments were performed 48
h after transfection, as previously described (12, 13, 15). Inward
rectifier potassium currents (IKir2.1) were recorded at room tem-
perature (21–23 °C) using the whole-cell patch-clamp technique
and filtered at half the sampling frequency (12, 13, 15). Series re-
sistance was compensated manually and 80% compensation
was achieved. Under our experimental conditions, no significant
voltage errors (,5 mV) because of series resistance were ex-
pected with the micropipettes used.
Experimental Design and Statistical Rationale—The total num-
ber of samples analyzed and the statistical tests used in the vari-
ous experiments are indicated throughout the text, e.g. triplicate
BioID experiments were performed, the number of transfected
cell batches (N) and number of cells (n) used in the patch-clamp-
ing experiments are shown, or the statistical significances of the
difference between the Kir2.1WT and Kir2.1D314-315 BioID experi-
ments were computed using a two-sample t test on the Log2-
transformed data.
RESULTS AND DISCUSSION
Kir2.1 Interactome Mapping Using BioID—Using the proxim-
ity-labeling technology BioID (16–18), we generated a map
of the Kir2.1 interactome (overall procedure is described in
Fig. 1). Both Kir2.1WT and Kir2.1D314-315, an ATS-associated
mutant protein for which Golgi export is impaired (4, 19,
20), were used as BirA*-tagged BioID baits. We performed
patch-clamping analyses of both the BirA*-tagged Kir2.1WT
and Kir2.1D314-315 bait proteins (supplemental Fig. S2). As
expected, HEK293 cells expressing BirA*-tagged Kir2.1WT,
but not mutant BirA*-tagged Kir2.1D314-315 cells, exhibited
the characteristic ability to strongly rectify, that is to pass
K1 current in the inward direction much more readily than
outward. Moreover, BirA*-tagged Kir2.1WT channels maintain
their sensitivity to Ba21 blocking (supplemental Fig. S2). As a
negative control, we used the TM-CTRL construct, a yeast
transmembrane domain fused to the BioID BirA* tag. We investi-
gated the subcellular localization of both Kir2.1WT and
Kir2.1D314-315 bait proteins as well as the TM-CTRL by IF stain-
ing (supplemental Fig. S3). After expression of the BirA*-
Kir2.1WT, BirA*-Kir2.1D314-315 and BirA*-TM-CTRL bait proteins
in HEK293 cells (supplemental Fig. S4) and purification of the bi-
otinylated proteins on streptavidin-agarose beads, the purified
protein extracts were subjected to MS/MS analysis for identifi-
cation. The Kir2.1WT, Kir2.1D314-315 and TM-CTRL baits were
each assessed in triplicate BioID experiments. A stringent set of
criteria were used for the selection of the Kir2.1 BioID hits: i) av-
erage SpC in either the Kir2.1WT or the Kir2.1D314-315 BioID
experiments . 10; ii) SAINT probability score (27, 28) . 0.9;
and iii) primary fold change FC-A score (28) .7. Our proteomic
screen resulted in the identification of 218 high-confidence
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Kir2.1 BioID hits, the vast majority of which are novel pu-
tative Kir2.1 direct or indirect interactors (supplemental
Table S3). Interestingly, some of the newly identified BioID
interactors include products of genes previously associ-
ated with physiological or pathophysiological function of
the myocardium, e.g. UTRN (29, 30) and PKP4 (31, 32), as
described in detail below. Curation of the literature and of
the functional data reported in PubMed for each of these
genes led to the identification of a dozen of known protein
complexes or functionally related biological modules in
our list of 218 high-confidence Kir2.1 BioID hits, e.g. the
cadherin adhesome and the COPII complex.
To assess the sensitivity of our BioID proteomic screen,
we measured the proportion of the previously described
Kir2.1 interactors that are also present in our list of 218 high-
confidence Kir2.1 BioID interactors. A review of several pro-
tein interaction repositories [BioGRID (33), IntAct (34), HPRD
(35), HuRI (36, 37)] identified 24 putative Kir2.1 protein inter-
actions. After literature curation, we selected 16 high-confi-
dence Kir2.1 interactions that had been observed in at least
two experiments and/or validated for their functional rele-
vance (supplemental Table S1). We note, though, that some
of these interactions have been studied using the Mus mus-
culus or Rattus norvegicus proteins, but not the human pro-
teins (columns I–J in supplemental Table S1). Out of all the
24 previously reported putative Kir2.1 interactors, 10 (;42%)
were identified in our BioID screen. Similarly, out of the 16
high-confidence Kir2.1 interactions, 7 (;44%) were identified
in our BioID screen, i.e. SAP97, CASK, CAV1, LIN7C,
AKAP5, Kir2.6 and Kir2.3 (supplemental Table S1 and S3).
This analysis suggests a high sensitivity of .40% for our
BioID assay. By comparison, the sensitivity of high-through-
put protein interaction mapping assays used on a proteome-
scale ranges from ;20 to ;35% (38).
Kir2.1WT versus Kir2.1D314-315 Interactome Profiling—Under-
standing the molecular mechanisms that govern the regula-
tion of inward rectifier potassium currents by Kir2.1 in both
normal and disease contexts should help uncover novel
FIG. 1.Overall procedure to generate the Kir2.1 BioID interactome map. Stable cells expressing BirA*-tagged Kir2.1WT, Kir2.1D314-315 or TM-
CTRL bait proteins were generated using the Flp-In T-Rex 293 cell line. Expression of the bait proteins was induced by tetracycline and cells were
treated with Supplemental biotin for 24 h. After cell lysis, biotinylated proteins were purified on streptavidin-agarose beads and digested with
trypsin. Tryptic peptides were analyzed using LC–MS/MS and proteins were identified using Proteome Discoverer. After applying a strin-
gent set of criteria, we identified 218 high-confidence Kir2.1 BioID hits. Using the normalized Kir2.1WT/D314-315 SpC ratio “R ”, we classified
the interactors in three categories: 75 Kir2.1WT-preferred interactors, 66 Kir2.1D314-315-preferred interactors and 77 Kir2.1WT/D314-315-neu-
tral interactors. CTRL: control; LC–MS/MS: liquid chromatography with tandem MS; SAINT: Significance Analysis of INTeractome; SpC:
spectral counts; TM: transmembrane; WT: WT.
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targets for therapeutic intervention in ATS1 and other Kir2.1-
associated channelopathies. Beyond interaction mapping,
our proteomic experiments also aims at capturing the differ-
ences between the interaction profiles of Kir2.1WT and
Kir2.1D314-315. Using the normalized Kir2.1WT/D314-315 SpC ra-
tio “R” (supplemental Table S3, columns AN-AP; see Meth-
ods for details about the calculation, normalization and statis-
tical analysis), we classified the 218 high-confidence Kir2.1
BioID hits: 75 tend to interact preferentially with Kir2.1WT,
66 interact preferentially with Kir2.1D314-315 and the remaining
77 BioID interactors interact with both the Kir2.1WT and
Kir2.1D314-315 proteins (FDR , 0.007; Fig. 2). For example,
the normalized SpC counts for UTRN in the BioID experiments
are: 86.0 SpC for Kir2.1WT and 0.9 SpC for Kir2.1D314-315,
i.e. r = 56.0 and p = 8 3 1024. UTRN is thus classified as a
Kir2.1WT-preferred interactor.
The ATS1-associated mutation Kir2.1D314-315 blocks Kir2.1
Golgi export (4, 19, 20). Hence, Kir2.1WT-preferred interactors
may encompass both: i) protein interactors that are directly
involved in the normal trafficking of Kir2.1, and ii) protein
interactors that, as an indirect consequence of the Golgi-
trapping, do not interact with Kir2.1D314-315 simply because it
is not present at the plasma membrane. Interestingly, out of
the 75 Kir2.1WT-preferred interactors, 13 of them have been
associated (mutation and/or GWAS hit) with one or several
heart-related traits or diseases, e.g. atrial fibrillation (AF) or
systolic/diastolic blood pressure (supplemental Table S3, col-
umn AR).
FIG. 2. Kir2.1WT versusKir2.1D314-315 interactome profiling. Variations in the Kir2.1WT and Kir2.1D314-315 interactome profiles are visualized in
a scatter plot representing the average Log2-transformed, normalized SpC counts for both the Kir2.1
WT (y axis) and Kir2.1D314-315 (x axis) bait pro-
teins. The Kir2.1 bait, Kir2.1WT-preferred interactors, Kir2.1D314-315-preferred interactors and Kir2.1WT/D314-315-neutral interactors are represented
as blue, green, red and gray dots, respectively.
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Most ATS mutants, including Kir2.1D314-315, exert a domi-
nant-negative effect on Kir2.1WT channels, as oppose to an
haploinsufficiency effect (20). Accordingly, protein interac-
tions involving Kir2.1D314-315-preferred interactors may also
encompass molecular mechanisms that are not properly
regulated in the presence of Kir2.1D314-315. For example, the
Kir2.1D314-315 mutation may result in the gain of an interaction
(or increased binding affinity) between Kir2.1D314-315 and a
protein present in the Golgi that perturbs normal trafficking
and results in the trapping of Kir2.1D314-315. On one hand, the
increased ability for Kir2.1D314-315 to interact with some of
these Kir2.1D314-315-mutant preferred interactors may be an
indirect consequence of the D314-315 mutation and these
Kir2.1D314-315-mutant preferred interactors are thus likely to
have low relevance to the disease. On the other hand, the
increased ability for Kir2.1D314-315 to interact with some of
these Kir2.1D314-315-mutant preferred interactors may be a
direct consequence of the D314-315 mutation and some of
these Kir2.1D314-315-mutant preferred interactors may thus be
possible direct contributing factors to the disease. Interest-
ingly, out of the 66 Kir2.1D314-315-preferred interactors, 10 of
them have been associated (mutation and/or GWAS hit) with
one or several heart-related traits or diseases, e.g. atrial fibril-
lation (AF) or systolic/diastolic blood pressure (supplemental
Table S3, column AR). Below, we discuss in details the
potential implications associated with some of these
Kir2.1WT-preferred interactors, e.g. UTRN, and Kir2.1D314-315-
preferred interactors, e.g. NAC and IGF1R.
The analysis of the variations in the interactome profiles of
Kir2.1WT and Kir2.1D314-315 allows us to identify protein com-
plexes or groups of functionally related proteins that, for the
most part, tend to interact primarily with either Kir2.1WT or
Kir2.1D314-315 (Fig. 3). For example, most of the proteins in
the MAGUK complex interact preferentially with Kir2.1WT (col-
ored in green in Fig. 3). In contrast, Kir2.1 interactors in the
Nascent polypeptide-associated complex (NAC) bind prefer-
entially to Kir2.1D314-315 (colored in red in Fig. 3). Interestingly,
the “Channels-Transporters” group encompasses proteins
that interact preferentially with either cytoplasmic membrane-
bound Kir2.1WT, Golgi-trapped Kir2.1D314-315 or that are
Kir2.1WT/D314-315-neutral interactors (colored in gray in Fig. 3).
This observation indicates that Kir2.1 not only interacts with
other channels-transporters at the cytoplasmic membrane
but that the co-trafficking of these proteins in the endoplas-
mic reticulum (ER) and Golgi apparatus is an important as-
pect of their function. Thus, the previously described
dynamic reciprocity for the regulation of Nav1.5 sodium and
Kir2.1 potassium channel expression, which controls cardiac
excitability and arrhythmia (12), likely extends to other chan-
nelosome protein complexes beyond Nav1.5.
Enrichment Analyses—To further extend our analysis of the
protein complexes and the groups of genes that interact with
Kir2.1, we performed a gene set enrichment analysis using
DAVID (39) (supplemental Table S4). We observed that
Kir2.1WT-preferred interactors are enriched for protein fami-
lies involved in cell adhesion [GO:0007155, Fold Enrichment
(FE) = 8, p = 2 3 1028], including integrin complex proteins
(GO:0008305, FE = 55, p = 6 3 1028) and cadherin adhe-
some proteins (GO:0098641, FE = 6.1, p = 9 3 1024). In
addition to the protein domains characteristic of integrin pro-
teins, e.g. InterPro domain IPR018184 (FE = 94, p = 3 3
1029), Kir2.1WT-preferred interactors also tend to contain
PDZ domains (IPR001478, FE = 15, p = 2 3 1027), further
highlighting the previously described key role of PDZ do-
main-scaffolding proteins in the modulation of Kir2.1 channe-
losomes (8). As expected, top KEGG pathways enriched in
Kir2.1WT-preferred interactors include arrhythmogenic right
ventricular cardiomyopathy (hsa05412), dilated cardiomyopa-
thy (hsa05414) and hypertrophic cardiomyopathy (hsa05410)
(FE . 17, p , 2 3 1025).
In contrast, Kir2.1D314-315-preferred interactors are enriched
for protein families involved in many aspects of intracellular
protein transport (GO:0006886, FE = 16, p = 3 3 10212),
including COPII (GO:0030127, FE = 145, p = 3 3 1028) and
ER to Golgi transport (GO:0012507, FE = 22, p = 7 3 1024).
On the same note, seven proteins containing the multipur-
pose docking adapter VHS domain, e.g. TOM1 and STAM,
which are associated with vesicular trafficking, are enriched
among the Kir2.1D314-315-preferred interactors (IPR002014,
FE = 222, p = 1 3 10213). Thus, in agreement with the previ-
ous reports (4, 19, 20), our data show that ATS1 pathogenesis
associated with the Kir2.1D314-315 mutation underlies malfunc-
tions in the mechanisms governing Kir2.1 trafficking from the
Golgi to the cytoplasmic membrane.
Kir2.1D314-315-preferred interactors are also linked to
ESCRT-0 (GO:0033565, FE = 289, p = 3 3 1025) and lyso-
some (hsa04142, FE = 7, p = 0.02), suggesting that this
ATS1 mutation leads to increased targeting of Kir2.1 to lyso-
somal degradation. These observations agree with the previ-
ous report by Kolb et al. that Kir2.1 degradation is primarily
lysosomal dependent and requires ESCRT (40). However,
using a pharmacological approach to inhibit either proteaso-
mal or vacuolar proteases, Kolb et al. also observed that
Kir2.1D314-315 mutation targets the channel for proteasomal
degradation rather than vacuolar-dependent degradation
(40). Though we indeed note the presence of PSMD1, the
26S proteasome nonATPase regulatory subunit 1, among the
Kir2.1D314-315-preferred interactors, our enrichment analysis
does not provide support to the “proteasome hypothesis”
but instead, strongly suggests that vacuolar-dependent deg-
radation remains an important route responsible for the
increased Kir2.1D314-315 protein turnover.
Strikingly, all the aforementioned functional attributes and
the vast majority of the gene sets are specifically enriched in
either Kir2.1WT-preferred interactors or Kir2.1D314-315-preferred
interactors, but not both. For example, out of the top 30 gene
sets enriched for Kir2.1WT-preferred interactors (p , 1 3 1023),
only one was also enriched in the Kir2.1D314-315-preferred
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interactors: basolateral plasma membrane (GO:0033565, FE =
6, p = 0.02) (supplemental Table S5). Similarly, out of the top
34 gene sets enriched for Kir2.1D314-315-preferred interactors
(p , 1 3 1023), only two were also enriched in the Kir2.1WT-pre-
ferred interactors (supplemental Table S5). This observation fur-
ther underscores the fact that the Kir2.1WT and Kir2.1D314-315
proteins obey to dramatically different fates in the cell.
Kir2.1 BioID Interactome: A Repository for Novel Biological
Hypotheses—The Kir2.1 BioID interactome data set repre-
sents a repository for numerous, novel biological hypotheses
for genes and molecular mechanisms implicated in Kir2.1-
associated cardiomyopathies. For example, out of the 218
high-confidence Kir2.1 interactors identified in our BioID
screen, 37 of them have been associated (mutation and/or
GWAS hit) with one or several heart-related traits or diseases,
e.g. atrial fibrillation (AF) or systolic/diastolic blood pressure
(supplemental Table S3, column AR). Below, we describe a
few examples: UTRN, NACA, IGF1R and PKP4.
UTRN was identified in our BioID screen as a Kir2.1WT-pre-
ferred interactor (normalized SpC counts: Kir2.1WT: 86.0 and
Kir2.1D314-315: 0.9; supplemental Table S3). Utrophin defi-
ciency worsens cardiac contractile dysfunction present in
dystrophin-deficient mice (29). Interestingly, a race-strati-
fied genome-wide gene-environment interaction associa-
tion study recently identified polymorphic variations in
the UTRN gene locus as potential risk factors in periph-
eral arterial disease (30). UTRN is part of the Dystrophin-
associated proteins (DAP) complex (41) and several other
DAP proteins interact with and modulate both sodium
and potassium channelosome protein complexes (8, 11,
42). This novel Kir2.1-UTRN interaction further underlines
the role of DAP in regulating these complexes and mal-
function of these molecular mechanisms may contribute
to pathophysiological conditions of the myocardium.
Nascent-Polypeptide-Associated Complex (NAC)—Our BioID
screen identified four NAC-associated proteins as Kir2.1D314-315-
preferred interactors, i.e. NACA, NACA2, BTF3 and BTF3L4. For
example, the normalized SpC counts for NACA are as follows:
Kir2.1WT: 24.4 and Kir2.1D314-315: 270.7 (supplemental Table S3).
The heterodimeric NAC protein complex binds to newly synthe-
sized polypeptide chains that lack a signal peptide motif as they
emerge from the ribosome, blocking interaction with the signal
recognition particle (SRP) and preventing mistranslocation to the
endoplasmic reticulum (43). Potential roles for NAC complex
thus range from protein folding chaperone to negative regulator
of translocation into the endoplasmic reticulum (43). We note,
though, that NACA has also been described as a transcription
factor (44), e.g. in collaboration with the heart-specific HDAC-
dependent repressor SMYD1 (45). The roles of NACA and NAC
in the cell remain to be comprehensively characterized.
Several observations link NACA to heart biology and dis-
eases. For example, GWAS studies have identified NACA
gene variants as potential risk factors in atrial fibrillation (AF)
(46, 47), or as a regulator of myocardial mass (48). In both
Drosophila melanogaster flies and Danio rerio zebrafish, the
knock-down of NACA, i.e. fly NACa and zebrafish skNAC,
results in severe cardiac muscle defects (48, 49). In mouse,
Naca deficiency results in embryonic lethality with cardiac
developmental defects (50). Park et al. originally linked this
phenotype to the role of NACA as a transcription factor and
as a major binding partner for SMYD1 in the developing heart
(50). The Kir2.1-NACA interaction suggests a more complex
role for NACA in the myocardium. Indeed, Kir2.1 deficiency
results not only in the loss of inward rectifier potassium
currents but also in developmental defects and dysmorphic
features, e.g. low-set ears, wide-set eyes, small mandible,
clinodactyly and syndactyly (4, 5, 51–53). The molecular
mechanism underlying these dysmorphic features is poorly
understood. The Kir2.1-NACA interaction provides a biophys-
ical bridge between the respective roles of these two proteins
during biological development in general and cardiomyogen-
esis in particular.
Cross-talks between Kir2.1 and Signal Transduction Path-
ways—The Kir2.1 interactor data set as a whole is enriched
for proteins involved in various aspects of signal transduc-
tion, i.e. enrichment is observed for all three classes of Kir2.1
interactors (WT, mutant and neutral; GO:0007165, FE . 2.4,
p , 0.01). Each class of interactors is enriched with different
signaling pathways, though. Examples of signaling pathways
over-represented in our Kir2.1WT-preferred interactor data set
include the ephrin receptor signaling pathway (GO:0048013,
FE = 12, p = 5 3 1023) and the Hedgehog signaling pathway
(KEGG hsa04340, FE = 26, p = 5 3 1023).
Likewise, the Kir2.1D314-315-preferred interactors are
enriched for proteins involved in the insulin-like growth factor
receptor signaling pathway, e.g. IGF1R and INSR
(GO:0048009, FE = 57, p = 1 3 1023). The normalized SpC
counts for IGF1R and INSR are as follows: Kir2.1WT: 12.1 and
15.7, and for Kir2.1D314-315: 31.6 and 35.4, respectively
(supplemental Table S3). GWAS studies have identified
IGF1R gene variants as potential risk factors in atrial fibrilla-
tion (AF) (46, 47), as well as a regulator of myocardial mass
FIG. 3. Graphical representation of the Kir2.1 BioID interactome. Protein complexes and groups of functionally related proteins encom-
passing 152 out of the 218 high-confidence Kir2.1 BioID hits are depicted in a cell. Major organelles in the cell (nucleus, endoplasmic reticu-
lum, Golgi apparatus and cytoplasmic membrane) are shown (light gray) in the background to roughly indicate the approximate subcellular
localization of the proteins in the cell. The Kir2.1WT-preferred interactors, Kir2.1D314-315-preferred interactors and Kir2.1WT/D314-315-neutral
interactors are represented as green, red and gray circles, respectively. The color intensity of each circle is an indicator of the strength of
the normalized Kir2.1WT/D314-315 SpC ratio “R” value. The size of each circle represents the average SpC counts observed in either the
Kir2.1WT or Kir2.1D314-315 BioID experiment (whichever is the largest is represented in the figure).
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(48) and global electrical heterogeneity ECG (54). We
hypothesize that the Kir2.1-IGF1R interaction is part of a mo-
lecular mechanism that underlies the functional associations
between IGF1R and cardiac physiology.
Could the Kir2.1-IGF1R interaction also help better
understand the potential role of Kir2.1 in diabetes? A func-
tional link between Kir2.1 and the insulin-like growth factor
receptor signaling pathway has been previously proposed.
As early as 1998, Wischmeyer et al. observed that treat-
ment of Xenopus oocytes with insulin was found to robustly
suppress IKir2.1 (55). Electrical activity plays a central role in
glucose-stimulated insulin secretion from human pancreatic
b-cells. We note that Kir2.1 is expressed in human pancre-
atic islets (56) and that functional Kir2.1 currents are pres-
ent in human b-cells (57). Riz et al. predicted that blocking
Kir2.1 channels increases the rate of insulin secretion and
that hyperactive Kir2.1 channels may lead to reduced insu-
lin secretion (57). Similarly, in a recent mathematical model,
Kir2.1 was predicted to be a critical actor in the regulation
of oscillations in cellular activity that underlie insulin pulsa-
tility in pancreatic islets cells lacking K(ATP) channels (58).
On the same note, several publications link abnormal QT
interval regulation and diabetes (59–61). Moreover, patients
with long QT syndrome associated to potassium channel
deficiency, e.g. KCNQ1 mutants, suffer from over-secretion
of insulin, hyperinsulinemia, and symptomatic hypoglyce-
mia (62). Our BioID data suggest that these functional
associations between Kir2.1 and the insulin pathway need
not be indirect but may also be mediated by biophysical
interactions between Kir2.1 channels and insulin pathway
proteins.
Desmosome—Several desmosome-associated proteins in-
teract with both Kir2.1WT and Kir2.1D314-315, e.g. JUP,
DSG2, DSC2 and PKP4 (supplemental Table S3). Desmo-
somes act as mechanical cell-cell adhesion junctions
maintaining the structural integrity of the tissue. Mutations
in the JUP, DSG2 and DSC2 genes have been associated
with Arrhythmogenic Right Ventricular Cardiomyopathy
(ARVC) (63). Actually, with ;half of ARVC patients carry-
ing a mutation in one of the genes encoding desmosomal
FIG. 4. Kir2.1 and PKP4 co-localize in adult ventricular myocytes. Immunofluorescence (IF) staining analyses of the subcellular localization
of Kir2.1 (A, red), Actinin (B, green) and PKP4 (C, light blue) in a freshly isolated rat adult ventricular myocytes. (D) Merge image. (E) Pixel intensity
profile of PKP4, Kir2.1 and actinin along a line in themerge image, i.e. blue arrow shown in (D) showing the striated co-localization of the three pro-
teins at the z-disks near the cardiac sarcomeres. (F) Differential interference contrast (DIC) image of the myocyte. (G–J) Zoomed in images of the
intercalated disks. Scale bars: 10mM. ID: intercalated disk.
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proteins expressed in the heart, ARVC can be considered
a disease of the desmosome (63). Mutations in the JUP
genes have also been associated with Naxos disease, a
diffuse nonepidermolytic palmoplantar keratoderma with
wooly hair and cardiomyopathy (64). We also note that
JUP mRNA is highly differentially expressed in AF (65).
FIG. 5.PKP4 is a positive regulator of IKir2.1.Patch-clamping analyses in HEK293 cells upon genetic perturbation ofPKP4, i.e. (A) upon overex-
pression of PKP4 and (B) upon CRISPR/Cas9-mediated depletion of PKP4. *P,0.05 versus control. N: number of transfected cell batches; n:
number of cells; OE: overexpression;KD: knock-down.
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Functional Validation of PKP4 by Immunofluorescence and
Patch-Clamp Analyses—PKP4 is one of the desmosome pro-
teins identified in our BioID experiment as interacting with
both Kir2.1WT and Kir2.1D314-315 (normalized SpC counts:
Kir2.1WT: 23.3 and Kir2.1D314-315: 7.6). PKP4 is a multifunc-
tional armadillo protein coordinating cell adhesion with cytos-
keletal organization that also has a role in vesicle transport
processes (66). Though less frequent than the ones observed
for the JUP, DSG2 and DSC2 genes, mutations in the PKP4
gene have been observed in ARVC patients (31, 32). Similarly
to many other Kir2.1 interactors (8), PKP4 carries a PDZ
binding site at its carboxyl terminus. We hypothesize that the
Kir2.1-PKP4 interaction contributes to the regulation of
Kir2.1.
As a first step toward validating the role of PKP4 as a reg-
ulator of Kir2.1, we investigated the subcellular localization of
both proteins by immunofluorescence (IF) staining in freshly
isolated adult rat ventricular myocytes. We observed that
Kir2.1 and PKP4 co-localize at intercalated disks and at z-
disks near the cardiac sarcomeres (Pearson correlation coef-
ficient = 0.85) (Fig. 4).
Finally, to assess the functional relevance of PKP4 to the
modulation of IKir2.1, we performed patch-clamp in the volt-
age clamp configuration (12, 13, 15) in a stable HEK293 cell
line expressing Kir2.1 upon genetic perturbation of PKP4
(Fig. 5). Upon PKP4 overexpression, we observed a gain of
IKir2.1 density (Fig. 5A). Accordingly, upon CRISPR/Cas9-
mediated depletion of PKP4, we observed a loss of IKir2.1
density (Fig. 5B). Therefore, in addition to interacting with
Kir2.1 (Fig. 2) and to being mutated in an ARVC patients (31,
32), PKP4 is a positive regulator of IKir2.1 density.
CONCLUSION
Evidence accumulated over the last 20 years strongly indi-
cates that potassium channels function depends on a com-
plex and dynamic ensemble of molecular events occurring in
various organelles in the cell that help in the assembly and
delivery of the right channel subunits to the right place in the
cell membrane at the right time. Understanding such molecu-
lar events should help uncover novel insights into how chan-
nelosome proteins and accessory proteins participate in the
control of cardiac excitability and the mechanisms of arrhyth-
mias. Using a BioID proteomic approach, we have generated
the most comprehensive Kir2.1 interactome map known to
date with 218 high-confidence Kir2.1 BioID hits, the vast ma-
jority of which are novel putative Kir2.1 interactors. Moreover,
our approach allowed us to identify novel proteins that inter-
act preferentially with either Kir2.1WT or the ATS1 mutant
Kir2.1D314-315, thus uncovering novel molecular mechanisms
underlying Kir2.1 function/dysfunction in ATS1. Our Kir2.1
interactome map represents a repository for numerous novel
biological hypotheses. Using patch-clamping, we verified the
functional relevance of one of our hits, PKP4, to the modula-
tion of IKir2.1, thus providing a molecular mechanism by which
PKP4 may be involved in ARVC. This result validates the
power of our BioID interactome approach in identifying func-
tionally relevant Kir2.1 interactors and modulators of IKir2.1.
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